160 related articles for article (PubMed ID: 21635826)
1. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
2. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
Yu YH; Shere Y; Vigneswaran N
Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661
[No Abstract] [Full Text] [Related]
3. Diffuse pigmentation of the palate.
Lewis DM
J Okla Dent Assoc; 2009 Nov; 100(8):24-5. PubMed ID: 19998620
[No Abstract] [Full Text] [Related]
4. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
5. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
6. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
8. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases.
Pascual JC; Matarredona J; Miralles J; Conesa V; Borras-Blasco J
Int J Dermatol; 2006 Dec; 45(12):1471-3. PubMed ID: 17184272
[No Abstract] [Full Text] [Related]
9. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
10. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
11. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
12. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
13. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
16. Imatinib-associated melanosis of the palate.
Roeker LE; Wolanskyj AP
Am J Hematol; 2014 May; 89(5):564. PubMed ID: 24030927
[No Abstract] [Full Text] [Related]
17. Oral lichenoid eruption associated with imatinib treatment.
Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
[No Abstract] [Full Text] [Related]
18. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
19. [Adverse effects of imatinib mesylate].
Isshiki I
Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Ianotto JC; Tempescul A; Amet Y; Grall P; Dalbies F; Eveillard JR; Guillerm G; Berthou C
Am J Hematol; 2012 Apr; 87(4):437-9. PubMed ID: 22287505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
